Ann Knoop
Overview
Explore the profile of Ann Knoop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kastora S, Pantiora E, Hong Y, Veeramani M, Azim Jr H, Chakrabarti R, et al.
Cancer Treat Rev
. 2025 Jan;
133:102880.
PMID: 39854791
Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely...
2.
Sode M, Nielsen K, Jensen M, Berg T, Knoop A, Ejlertsen B, et al.
Acta Oncol
. 2024 Nov;
63:878-886.
PMID: 39543845
Background And Purpose: We investigated the prognosis of breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2), as previous studies have found varying impacts on...
3.
Gehrchen M, Berg T, Garly R, Jensen M, Esser-Naumann S, Ronlev J, et al.
BJC Rep
. 2024 Nov;
2(1):44.
PMID: 39516670
Background: Initial treatment for advanced ER-positive/HER2-negative breast cancer involves a CDK 4/6 inhibitor (CDK 4/6i). Recent overall survival (OS) analyses led the Danish Medical Council to exclude palbociclib as preferred...
4.
Celik A, Berg T, Gibson M, Jensen M, Kumler I, Esser-Naumann S, et al.
Acta Oncol
. 2024 Jun;
63:494-502.
PMID: 38912829
Material And Methods: The study utilized the Danish Breast Cancer Group (DBCG) database and was conducted retrospectively across all Danish oncology departments. Inclusion criteria were female patients, with HER2-normal advanced...
5.
Reznitsky F, Jensen J, Knoop A, Jensen M, Laenkholm A
Acta Oncol
. 2023 Nov;
62(12):1913-1920.
PMID: 37961947
Background: Tumor-infiltrating lymphocytes (TILs) have predictive and prognostic potential in HER2-positive breast cancer (HER2+ BC). Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein, with important roles in the tumor...
6.
Nielsen K, Sode M, Jensen M, Berg T, Knoop A, Ejlertsen B, et al.
Breast Cancer Res
. 2023 Nov;
25(1):139.
PMID: 37946261
Background: Considering the recent advancements in the treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2), we aimed to examine inter-laboratory variability in the...
7.
Pappot H, Bjornsson B, Krause O, Baeksted C, Bidstrup P, Dalton S, et al.
Breast Cancer
. 2023 Nov;
31(1):148-153.
PMID: 37940813
Background: Patient-reported outcome (PRO) data may help us better understand the life of breast cancer patients. We have previously collected PRO data in a national Danish breast cancer study in...
8.
Celik A, Berg T, Jensen M, Jakobsen E, Nielsen H, Kumler I, et al.
Breast Cancer (Auckl)
. 2023 Oct;
17:11782234231203292.
PMID: 37810797
Background: Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype of breast cancer with poor survival. Currently, the literature lacks comprehensive real-world evidence on locally recurrent and mTNBC patients. To...
9.
Garly R, Knoop A, Jensen M, Berg T, Nielsen H, Kumler I
Dan Med J
. 2023 Aug;
70(9).
PMID: 37622644
Introduction: The Danish Medicines Council recommends that patients with estrogen receptor and human epidermal growth factor receptor 2-negative, programmed death-ligand 1 (PD-L1)-positive advanced breast cancer receive atezolizumab in combination with...
10.
Artzi D, Berg T, Celik A, Kumler I, Kenholm J, Al-Rawi S, et al.
Acta Oncol
. 2023 Jun;
62(6):601-607.
PMID: 37338513
Background: The purpose was to investigate the treatment flow of patients with HER2-positive metastatic breast cancer (mBC), progression-free survival (PFS) and overall survival (OS) across treatment lines and adherence to...